Status In progress
Process STA pre-2018
ID number 982

Provisional Schedule

Expected publication 19 September 2018

Project Team

Project lead Stephanie Callaghan

Email enquiries

Consultees

Companies sponsors Pfizer
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups CR-UK
  Leukaemia CARE
Professional groups Association of Cancer Physicians
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare Ltd (cytarabine, etoposide, fludarabine, idarubicin, mitoxantrone) (confidentiality agreement not signed, not participating)
  Actavis UK Ltd (etoposide, fludarabine) (confidentiality agreement not signed, not participating)
  Aspen (thioguanine)
  Baxter Healthcare Ltd (mitoxantrone) (confidentiality agreement not signed, not participating)
  Hospira UK Ltd (cytarabine, mitoxantrone) (confidentiality agreement not signed, not participating)
  Medac GmbH (etoposide) (confidentiality agreement not signed, not participating)
  NordMedica A/S (amsacrine) (confidentiality agreement not signed, not participating)
  Novartis (midostaurin)
  Pfizer Ltd (cytarabine, idarubicin)
  Sanofi (fludarabine) (confidentiality agreement not signed, not participating)
  Sandoz Ltd (fludarabine) (confidentiality agreement not signed, not participating)
  Zentiva (daunorubicin) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
27 June 2018 Committee meeting: 2
25 May 2018 - 18 June 2018 Appraisal consultation: 1
26 April 2018 Committee meeting: 1
06 November 2017 This appraisal is to be rescheduled to allow the company (Pfizer) additional time to resolve unforeseen issues with their economic modelling. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization.
14 September 2017 Invitation to participate
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance